{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "from IngestDrugSynonyms import IngestDrugSynonyms"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "%load_ext autoreload\n",
    "%autoreload 2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<style>.container { width:100% !important; }</style>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/ben/Projects/Graphs4GoodHackathon/ProjectDomino/.Domino/lib/python3.7/site-packages/ipykernel_launcher.py:3: FutureWarning: Passing a negative integer is deprecated in version 1.0 and will not be supported in future version. Instead, use None to not limit the column width.\n",
      "  This is separate from the ipykernel package so we can avoid doing imports until\n"
     ]
    }
   ],
   "source": [
    "from IPython.core.display import display, HTML\n",
    "display(HTML(\"<style>.container { width:100% !important; }</style>\"))\n",
    "pd.set_option('display.max_colwidth', -1)\n",
    "pd.set_option('display.max_rows', 500)\n",
    "pd.set_option('display.max_columns', 500)\n",
    "pd.set_option('display.width', 1000)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "drugSynonym = IngestDrugSynonyms()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2020-04-07 15:51:58,259 - > 351 studies found by 'covid-19' keyword\n",
      "2020-04-07 15:52:11,769 - > 351 studies found by 'SARS-CoV-2' keyword\n",
      "2020-04-07 15:52:25,084 - > 301 studies found by 'coronavirus' keyword\n"
     ]
    }
   ],
   "source": [
    "drugSynonym.scrapeData()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "drugSynonym.filterData()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>TrialID</th>\n",
       "      <th>Last Refreshed on</th>\n",
       "      <th>Public title</th>\n",
       "      <th>Scientific title</th>\n",
       "      <th>Acronym</th>\n",
       "      <th>Primary sponsor</th>\n",
       "      <th>Date registration</th>\n",
       "      <th>Date registration3</th>\n",
       "      <th>Export date</th>\n",
       "      <th>Source Register</th>\n",
       "      <th>web address</th>\n",
       "      <th>Recruitment Status</th>\n",
       "      <th>other records</th>\n",
       "      <th>Inclusion agemin</th>\n",
       "      <th>Inclusion agemax</th>\n",
       "      <th>Inclusion gender</th>\n",
       "      <th>Date enrollement</th>\n",
       "      <th>Target size</th>\n",
       "      <th>Study type</th>\n",
       "      <th>Study design</th>\n",
       "      <th>Phase</th>\n",
       "      <th>Countries</th>\n",
       "      <th>Contact Firstname</th>\n",
       "      <th>Contact Lastname</th>\n",
       "      <th>Contact Address</th>\n",
       "      <th>Contact Email</th>\n",
       "      <th>Contact Tel</th>\n",
       "      <th>Contact Affiliation</th>\n",
       "      <th>Inclusion Criteria</th>\n",
       "      <th>Exclusion Criteria</th>\n",
       "      <th>Condition</th>\n",
       "      <th>Intervention</th>\n",
       "      <th>Primary outcome</th>\n",
       "      <th>results date posted</th>\n",
       "      <th>results date completed</th>\n",
       "      <th>results url link</th>\n",
       "      <th>Retrospective flag</th>\n",
       "      <th>Bridging flag truefalse</th>\n",
       "      <th>Bridged type</th>\n",
       "      <th>results yes no</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>ChiCTR2000029953</td>\n",
       "      <td>43878.0</td>\n",
       "      <td>Construction and Analysis of Prognostic Predictive Model of Novel Coronavirus Pneumonia (COVID-19)</td>\n",
       "      <td>Construction and Analysis of Prognostic Predictive Model of Novel Coronavirus Pneumonia (COVID-19)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Zhongnan Hospital of Wuhan University</td>\n",
       "      <td>43878.0</td>\n",
       "      <td>20200217.0</td>\n",
       "      <td>43834.660579</td>\n",
       "      <td>ChiCTR</td>\n",
       "      <td>http://www.chictr.org.cn/showproj.aspx?proj=49217</td>\n",
       "      <td>Not Recruiting</td>\n",
       "      <td>No</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Both</td>\n",
       "      <td>43862.0</td>\n",
       "      <td>survival group:200;died:200;</td>\n",
       "      <td>Observational study</td>\n",
       "      <td>Factorial</td>\n",
       "      <td>NaN</td>\n",
       "      <td>China</td>\n",
       "      <td>Yan Zhao</td>\n",
       "      <td>NaN</td>\n",
       "      <td>169 Donghu Road, Wuchang District, Wuhan, Hubei, China</td>\n",
       "      <td>doctoryanzhao@whu.edu.cn</td>\n",
       "      <td>+86 13995577963</td>\n",
       "      <td>Emergency Department of Zhongnan Hospital of Wuhan University</td>\n",
       "      <td>Inclusion criteria: 2019-nCoV-infected pneumonia diagnosed patients, the diagnostic criteria refer to \"guideline of the diagnose and treatment of 2019-nCoV (trial)\" published by National Health Committees of Peoples' Republic Country \"</td>\n",
       "      <td>Exclusion criteria: Patients diagnosed with pneumonia of age &lt;15 years diagnosed according to\"guideline of the diagnose and treatment of 2019-nCoV (tested)\" published by National Health Committees of Peoples' Republic Country;  Suspected patient with vira</td>\n",
       "      <td>2019-nCoV Pneumonia</td>\n",
       "      <td>survival group:none;died:none;</td>\n",
       "      <td>duration of in hospital;in hospital mortality;the 28s day' mortality after admission;duration of ICU stay;</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>ChiCTR2000029935</td>\n",
       "      <td>43878.0</td>\n",
       "      <td>A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)</td>\n",
       "      <td>A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>HwaMei Hospital, University of Chinese Academy of Sciences</td>\n",
       "      <td>43877.0</td>\n",
       "      <td>20200216.0</td>\n",
       "      <td>43834.660579</td>\n",
       "      <td>ChiCTR</td>\n",
       "      <td>http://www.chictr.org.cn/showproj.aspx?proj=49607</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>No</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Both</td>\n",
       "      <td>43867.0</td>\n",
       "      <td>Case series:100;</td>\n",
       "      <td>Interventional study</td>\n",
       "      <td>Single arm</td>\n",
       "      <td>NaN</td>\n",
       "      <td>China</td>\n",
       "      <td>Ting Cai</td>\n",
       "      <td>NaN</td>\n",
       "      <td>41 Xibei Street, Ningbo, Zhejiang, China</td>\n",
       "      <td>caiting@ucas.ac.cn</td>\n",
       "      <td>+86 13738498188</td>\n",
       "      <td>HwaMei Hospital, University of Chinese Academy of Sciences</td>\n",
       "      <td>Inclusion criteria: Patients aged 18 or older, and meet the diagnostic criteria of Diagnosis and Treatment Scheme of Novel Coronavirus Infected Pneumonia published by the National Health Commission.\\r&lt;br&gt;Criteria for diagnosis (meet all the following crite</td>\n",
       "      <td>Exclusion criteria: 1. Female patients during pregnancy; \\r&lt;br&gt;2. Patients with known allergy to chloroquine; \\r&lt;br&gt;3. Patients with haematological diseases; \\r&lt;br&gt;4. Patients with chronic liver or kidney diseases at the end stage; \\r&lt;br&gt;5. Patients with arrh</td>\n",
       "      <td>Novel Coronavirus Pneumonia (COVID-19)</td>\n",
       "      <td>Case series:Treated with conventional treatment combined with Chloroquine Phosphate;</td>\n",
       "      <td>Length of hospital stay;</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>No</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ChiCTR2000029850</td>\n",
       "      <td>43878.0</td>\n",
       "      <td>Study on convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19)</td>\n",
       "      <td>Effecacy and safty of convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19): a prospective cohort study</td>\n",
       "      <td>NaN</td>\n",
       "      <td>The First Affiliated Hospital of Zhejiang University School of Medicine</td>\n",
       "      <td>43876.0</td>\n",
       "      <td>20200215.0</td>\n",
       "      <td>43834.660579</td>\n",
       "      <td>ChiCTR</td>\n",
       "      <td>http://www.chictr.org.cn/showproj.aspx?proj=49533</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>No</td>\n",
       "      <td>16.0</td>\n",
       "      <td>99.0</td>\n",
       "      <td>Male</td>\n",
       "      <td>43876.0</td>\n",
       "      <td>experimental group:10;control group:10;</td>\n",
       "      <td>Interventional study</td>\n",
       "      <td>Non randomized control</td>\n",
       "      <td>0.0</td>\n",
       "      <td>China</td>\n",
       "      <td>Xiaowei Xu</td>\n",
       "      <td>NaN</td>\n",
       "      <td>79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China</td>\n",
       "      <td>xxw69@126.com</td>\n",
       "      <td>+86 13605708066</td>\n",
       "      <td>The First Affiliated Hospital of Zhejiang University, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Disease</td>\n",
       "      <td>Inclusion criteria: 1. Laboratory confirmed diagnosis of COVID19 infection by RT-PCR;\\r&lt;br&gt;2. Aged &gt; 18 years;\\r&lt;br&gt;3. Written informed consent given by the patient or next-of-kin;\\r&lt;br&gt;4. Clinical deterioration despite conventional treatment that required i</td>\n",
       "      <td>Exclusion criteria: 1. Hypersensitive to immunoglobulin;\\r&lt;br&gt;2. Have immunoglobulin A deficiency.</td>\n",
       "      <td>Novel Coronavirus Pneumonia  (COVID-19)</td>\n",
       "      <td>experimental group:standardized comprehensive treatment combined with convalescent plasma treatment;control group:standardized comprehensive treatment;</td>\n",
       "      <td>Fatality rate;</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Yes</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>ChiCTR2000029814</td>\n",
       "      <td>43878.0</td>\n",
       "      <td>Clinical Trial for Integrated Chinese and Western Medicine in the Treatment of Children with Novel Coronavirus Pneumonia (COVID-19)</td>\n",
       "      <td>Clinical Trial for Integrated Chinese and Western Medicine in the Treatment of Children with Novel Coronavirus Pneumonia (COVID-19)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Children's Hospital of Fudan University</td>\n",
       "      <td>43875.0</td>\n",
       "      <td>20200214.0</td>\n",
       "      <td>43834.660579</td>\n",
       "      <td>ChiCTR</td>\n",
       "      <td>http://www.chictr.org.cn/showproj.aspx?proj=49387</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>No</td>\n",
       "      <td>0.0</td>\n",
       "      <td>18.0</td>\n",
       "      <td>Both</td>\n",
       "      <td>43875.0</td>\n",
       "      <td>control group:15;experimental group:15;</td>\n",
       "      <td>Interventional study</td>\n",
       "      <td>Non randomized control</td>\n",
       "      <td>0.0</td>\n",
       "      <td>China</td>\n",
       "      <td>Zhai Xiaowen</td>\n",
       "      <td>NaN</td>\n",
       "      <td>399 Wanyuan Road, Minhang District, Shanghai</td>\n",
       "      <td>zhaixiaowendy@163.com</td>\n",
       "      <td>+86 64931902</td>\n",
       "      <td>Children's Hospital of Fudan University</td>\n",
       "      <td>Inclusion criteria: Children diagnosed with novel coronavirus pneumonia through epidemiological history, clinical symptoms, and nucleic acid test results.</td>\n",
       "      <td>Exclusion criteria: No exclusion criteria</td>\n",
       "      <td>Novel Coronavirus Pneumonia  (COVID-19)</td>\n",
       "      <td>control group:Western Medicine;experimental group:Integrated Traditional Chinese and Western Medicine;</td>\n",
       "      <td>Time fo fever reduction;Time of nucleic acid negative;Severe conversion rate;Improvement time of respiratory symptoms;</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Yes</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT04245631</td>\n",
       "      <td>43878.0</td>\n",
       "      <td>Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV</td>\n",
       "      <td>Development of a Simple, Fast and Portable Recombinase Aided Amplification (RAA) Assay for 2019-nCoV</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Beijing Ditan Hospital</td>\n",
       "      <td>43856.0</td>\n",
       "      <td>20200126.0</td>\n",
       "      <td>43834.660579</td>\n",
       "      <td>ClinicalTrials.gov</td>\n",
       "      <td>https://clinicaltrials.gov/show/NCT04245631</td>\n",
       "      <td>Recruiting</td>\n",
       "      <td>No</td>\n",
       "      <td>1 Year</td>\n",
       "      <td>90 Years</td>\n",
       "      <td>All</td>\n",
       "      <td>43831.0</td>\n",
       "      <td>50.0</td>\n",
       "      <td>Observational</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>China</td>\n",
       "      <td>; ;</td>\n",
       "      <td>Yao Xie, Doctor;Yao Xie, Doctor;Yao Xie, Doctor</td>\n",
       "      <td>NaN</td>\n",
       "      <td>;xieyao00120184@sina.com;xieyao00120184@sina.com</td>\n",
       "      <td>;8610-84322200;8610-84322200</td>\n",
       "      <td>Department of Hepatology, Division 2, Beijing Ditan Hospital;</td>\n",
       "      <td>\\r&lt;br&gt;        Inclusion Criteria:\\r&lt;br&gt;\\r&lt;br&gt;          -  1. Suspected cases (formerly observed cases)\\r&lt;br&gt;\\r&lt;br&gt;        Meet the following 2 at the same time:\\r&lt;br&gt;\\r&lt;br&gt;        Epidemiological history There was a history of travel or residence in Wuhan within</td>\n",
       "      <td>NaN</td>\n",
       "      <td>New Coronavirus</td>\n",
       "      <td>Diagnostic Test: Recombinase aided amplification (RAA) assay</td>\n",
       "      <td>Detection sensitivity is greater than 95%;Detection specificity is greater than 95%</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Yes</td>\n",
       "      <td>0</td>\n",
       "      <td></td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "            TrialID  Last Refreshed on                                                                                                                         Public title                                                                                                                                                                                                                                                 Scientific title Acronym                                                          Primary sponsor  Date registration  Date registration3   Export date     Source Register                                        web address Recruitment Status other records Inclusion agemin Inclusion agemax Inclusion gender  Date enrollement                              Target size            Study type            Study design Phase Countries Contact Firstname                                 Contact Lastname                                                   Contact Address  \\\n",
       "0  ChiCTR2000029953  43878.0            Construction and Analysis of Prognostic Predictive Model of Novel Coronavirus Pneumonia (COVID-19)                                   Construction and Analysis of Prognostic Predictive Model of Novel Coronavirus Pneumonia (COVID-19)                                                                                                                                                               NaN     Zhongnan Hospital of Wuhan University                                    43878.0            20200217.0          43834.660579  ChiCTR              http://www.chictr.org.cn/showproj.aspx?proj=49217  Not Recruiting     No            NaN              NaN              Both             43862.0           survival group:200;died:200;             Observational study   Factorial               NaN   China     Yan Zhao          NaN                                              169 Donghu Road, Wuchang District, Wuhan, Hubei, China             \n",
       "1  ChiCTR2000029935  43878.0            A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)                A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)                                                                                                                                            NaN     HwaMei Hospital, University of Chinese Academy of Sciences               43877.0            20200216.0          43834.660579  ChiCTR              http://www.chictr.org.cn/showproj.aspx?proj=49607  Recruiting         No            NaN              NaN              Both             43867.0           Case series:100;                         Interventional study  Single arm              NaN   China     Ting Cai          NaN                                              41 Xibei Street, Ningbo, Zhejiang, China                           \n",
       "2  ChiCTR2000029850  43878.0            Study on convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19)                               Effecacy and safty of convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19): a prospective cohort study                                                                                                                  NaN     The First Affiliated Hospital of Zhejiang University School of Medicine  43876.0            20200215.0          43834.660579  ChiCTR              http://www.chictr.org.cn/showproj.aspx?proj=49533  Recruiting         No            16.0             99.0             Male             43876.0           experimental group:10;control group:10;  Interventional study  Non randomized control  0.0   China     Xiaowei Xu        NaN                                              79 Qingchun Road, Shangcheng District, Hangzhou, Zhejiang, China   \n",
       "3  ChiCTR2000029814  43878.0            Clinical Trial for Integrated Chinese and Western Medicine in the Treatment of Children with Novel Coronavirus Pneumonia (COVID-19)  Clinical Trial for Integrated Chinese and Western Medicine in the Treatment of Children with Novel Coronavirus Pneumonia (COVID-19)                                                                                                                              NaN     Children's Hospital of Fudan University                                  43875.0            20200214.0          43834.660579  ChiCTR              http://www.chictr.org.cn/showproj.aspx?proj=49387  Recruiting         No            0.0              18.0             Both             43875.0           control group:15;experimental group:15;  Interventional study  Non randomized control  0.0   China     Zhai Xiaowen      NaN                                              399 Wanyuan Road, Minhang District, Shanghai                       \n",
       "4  NCT04245631       43878.0            Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV                                       Development of a Simple, Fast and Portable Recombinase Aided Amplification (RAA) Assay for 2019-nCoV                                                                                                                                                             NaN     Beijing Ditan Hospital                                                   43856.0            20200126.0          43834.660579  ClinicalTrials.gov  https://clinicaltrials.gov/show/NCT04245631        Recruiting         No            1 Year           90 Years         All              43831.0           50.0                                     Observational         NaN                     NaN   China      ; ;              Yao Xie, Doctor;Yao Xie, Doctor;Yao Xie, Doctor  NaN                                                                \n",
       "\n",
       "                                      Contact Email                   Contact Tel                                                                                                                                                                      Contact Affiliation                                                                                                                                                                                                                                                      Inclusion Criteria                                                                                                                                                                                                                                                   Exclusion Criteria                                Condition                                                                                                                                             Intervention  \\\n",
       "0  doctoryanzhao@whu.edu.cn                          +86 13995577963               Emergency Department of Zhongnan Hospital of Wuhan University                                                                                                                            Inclusion criteria: 2019-nCoV-infected pneumonia diagnosed patients, the diagnostic criteria refer to \"guideline of the diagnose and treatment of 2019-nCoV (trial)\" published by National Health Committees of Peoples' Republic Country \"                             Exclusion criteria: Patients diagnosed with pneumonia of age <15 years diagnosed according to\"guideline of the diagnose and treatment of 2019-nCoV (tested)\" published by National Health Committees of Peoples' Republic Country;  Suspected patient with vira      2019-nCoV Pneumonia                      survival group:none;died:none;                                                                                                                            \n",
       "1  caiting@ucas.ac.cn                                +86 13738498188               HwaMei Hospital, University of Chinese Academy of Sciences                                                                                                                               Inclusion criteria: Patients aged 18 or older, and meet the diagnostic criteria of Diagnosis and Treatment Scheme of Novel Coronavirus Infected Pneumonia published by the National Health Commission.\\r<br>Criteria for diagnosis (meet all the following crite        Exclusion criteria: 1. Female patients during pregnancy; \\r<br>2. Patients with known allergy to chloroquine; \\r<br>3. Patients with haematological diseases; \\r<br>4. Patients with chronic liver or kidney diseases at the end stage; \\r<br>5. Patients with arrh  Novel Coronavirus Pneumonia (COVID-19)   Case series:Treated with conventional treatment combined with Chloroquine Phosphate;                                                                      \n",
       "2  xxw69@126.com                                     +86 13605708066               The First Affiliated Hospital of Zhejiang University, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Disease  Inclusion criteria: 1. Laboratory confirmed diagnosis of COVID19 infection by RT-PCR;\\r<br>2. Aged > 18 years;\\r<br>3. Written informed consent given by the patient or next-of-kin;\\r<br>4. Clinical deterioration despite conventional treatment that required i      Exclusion criteria: 1. Hypersensitive to immunoglobulin;\\r<br>2. Have immunoglobulin A deficiency.                                                                                                                                                                   Novel Coronavirus Pneumonia  (COVID-19)  experimental group:standardized comprehensive treatment combined with convalescent plasma treatment;control group:standardized comprehensive treatment;   \n",
       "3  zhaixiaowendy@163.com                             +86 64931902                  Children's Hospital of Fudan University                                                                                                                                                  Inclusion criteria: Children diagnosed with novel coronavirus pneumonia through epidemiological history, clinical symptoms, and nucleic acid test results.                                                                                                              Exclusion criteria: No exclusion criteria                                                                                                                                                                                                                            Novel Coronavirus Pneumonia  (COVID-19)  control group:Western Medicine;experimental group:Integrated Traditional Chinese and Western Medicine;                                                    \n",
       "4  ;xieyao00120184@sina.com;xieyao00120184@sina.com  ;8610-84322200;8610-84322200  Department of Hepatology, Division 2, Beijing Ditan Hospital;                                                                                                                            \\r<br>        Inclusion Criteria:\\r<br>\\r<br>          -  1. Suspected cases (formerly observed cases)\\r<br>\\r<br>        Meet the following 2 at the same time:\\r<br>\\r<br>        Epidemiological history There was a history of travel or residence in Wuhan within  NaN                                                                                                                                                                                                                                                                  New Coronavirus                          Diagnostic Test: Recombinase aided amplification (RAA) assay                                                                                              \n",
       "\n",
       "                                                                                                          Primary outcome  results date posted  results date completed  results url link Retrospective flag Bridging flag truefalse Bridged type  results yes no  \n",
       "0  duration of in hospital;in hospital mortality;the 28s day' mortality after admission;duration of ICU stay;             NaN                  NaN                     NaN                No                 0                                   NaN              \n",
       "1  Length of hospital stay;                                                                                               NaN                  NaN                     NaN                No                 0                                   NaN              \n",
       "2  Fatality rate;                                                                                                         NaN                  NaN                     NaN                Yes                0                                   NaN              \n",
       "3  Time fo fever reduction;Time of nucleic acid negative;Severe conversion rate;Improvement time of respiratory symptoms; NaN                  NaN                     NaN                Yes                0                                   NaN              \n",
       "4  Detection sensitivity is greater than 95%;Detection specificity is greater than 95%                                    NaN                  NaN                     NaN                Yes                0                                   NaN              "
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "drugSynonym.internationalstudies.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Common name</th>\n",
       "      <th>Synonyms</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Lepirudin</td>\n",
       "      <td>Hirudin variant-1 | Lepirudin recombinant</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Cetuximab</td>\n",
       "      <td>Cetuximab | Cétuximab | Cetuximabum | Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Dornase alfa</td>\n",
       "      <td>Deoxyribonuclease (human clone 18-1 protein moiety) | Dornasa alfa | Dornase alfa, recombinant | Dornase alpha | Recombinant deoxyribonuclease (DNAse)</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Denileukin diftitox</td>\n",
       "      <td>Denileukin | Interleukin-2/diptheria toxin fusion protein</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Etanercept</td>\n",
       "      <td>Etanercept | etanercept-szzs | etanercept-ykro | Recombinant human TNF | rhu TNFR:Fc | rhu-TNFR:Fc | TNFR-Immunoadhesin</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "           Common name                                                                                                                                                                                                             Synonyms\n",
       "0  Lepirudin            Hirudin variant-1 | Lepirudin recombinant                                                                                                                                                                          \n",
       "1  Cetuximab            Cetuximab | Cétuximab | Cetuximabum | Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer\n",
       "2  Dornase alfa         Deoxyribonuclease (human clone 18-1 protein moiety) | Dornasa alfa | Dornase alfa, recombinant | Dornase alpha | Recombinant deoxyribonuclease (DNAse)                                                             \n",
       "3  Denileukin diftitox  Denileukin | Interleukin-2/diptheria toxin fusion protein                                                                                                                                                          \n",
       "4  Etanercept           Etanercept | etanercept-szzs | etanercept-ykro | Recombinant human TNF | rhu TNFR:Fc | rhu-TNFR:Fc | TNFR-Immunoadhesin                                                                                            "
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "drugSynonym.drug_vocab_reduced.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "13475"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(drugSynonym.drug_vocab)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "inter = drugSynonym.internationalstudies"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.7"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
